286 studies found for:    "Breast cancer male"
Show Display Options
Rank Status Study
21 Recruiting Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: veliparib;   Drug: paclitaxel;   Drug: carboplatin;   Other: pharmacological study;   Other: laboratory biomarker analysis
22 Active, not recruiting Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Biological: sargramostim;   Drug: rintatolimod;   Other: laboratory biomarker analysis
23 Suspended Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer Or Other Cancers
Conditions: HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Male Breast Cancer;   Malignant Neoplasm;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: triciribine phosphate;   Drug: paclitaxel;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
24 Active, not recruiting Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Male Breast Cancer;   Recurrent Adult Brain Tumor;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Stage III Pancreatic Cancer;   Stage III Renal Cell Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Melanoma;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Melanoma;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IV Breast Cancer;   Stage IV Melanoma;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Drug: cediranib maleate;   Other: pharmacological study;   Other: laboratory biomarker analysis
25 Terminated
Has Results
Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
Conditions: Male Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: oblimersen sodium;   Drug: doxorubicin hydrochloride;   Drug: docetaxel;   Biological: filgrastim;   Biological: pegfilgrastim;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Other: laboratory biomarker analysis
26 Not yet recruiting Stereotactic Radiosurgery in Treating Patients With Metastatic Breast Cancer, Non-Small Cell Lung Cancer, or Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Male Breast Cancer;   Recurrent Breast Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Prostate Cancer;   Stage IV Breast Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Prostate Cancer
Intervention: Radiation: stereotactic radiosurgery
27 Completed Sorafenib in Treating Patients With Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
28 Not yet recruiting Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
Conditions: HER2-negative Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: CD105/Yb-1/SOX2/CDH3/MDM2 multiplasmid vaccine;   Other: laboratory biomarker analysis
29 Withdrawn Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer
Conditions: Ductal Breast Carcinoma in Situ;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Male Breast Cancer;   Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate;   Mucinous Ductal Breast Carcinoma;   Papillary Ductal Breast Carcinoma;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Tubular Ductal Breast Carcinoma
Interventions: Radiation: external beam radiation therapy;   Other: questionnaire administration;   Procedure: therapeutic conventional surgery
30 Completed Decitabine in Treating Patients With Advanced Solid Tumors
Conditions: Male Breast Cancer;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Melanoma;   Stage III Melanoma;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Melanoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: decitabine;   Other: pharmacological study;   Other: laboratory biomarker analysis
31 Active, not recruiting Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
Conditions: Central Nervous System Metastases;   Invasive Ductal Breast Carcinoma;   Invasive Ductal Breast Carcinoma With Predominant Intraductal Component;   Invasive Lobular Breast Carcinoma;   Invasive Lobular Breast Carcinoma With Predominant in Situ Component;   Liver Metastases;   Lobular Breast Carcinoma in Situ;   Lung Metastases;   Male Breast Cancer;   Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate;   Mucinous Ductal Breast Carcinoma;   Papillary Ductal Breast Carcinoma;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Tubular Ductal Breast Carcinoma;   Tumors Metastatic to Brain
Interventions: Radiation: hyperfractionated radiation therapy;   Other: laboratory biomarker analysis;   Radiation: stereotactic radiosurgery
32 Active, not recruiting Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Other: laboratory biomarker analysis
33 Completed FR901228 in Treating Patients With Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: romidepsin;   Other: laboratory biomarker analysis
34 Completed Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: trastuzumab;   Biological: aldesleukin;   Other: laboratory biomarker analysis;   Other: pharmacological study
35 Recruiting Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: eribulin mesylate;   Other: laboratory biomarker analysis
36 Active, not recruiting Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
Conditions: Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: tipifarnib;   Drug: paclitaxel;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: pegfilgrastim;   Procedure: conventional surgery;   Procedure: axillary lymph node dissection
37 Completed AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Recurrent Renal Cell Cancer;   Stage IV Breast Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer;   Stage IV Renal Cell Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: AFP464;   Other: pharmacological study;   Other: laboratory biomarker analysis
38 Completed Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Inflammatory Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IIIB Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: tamoxifen citrate;   Drug: busulfan;   Drug: thiotepa;   Drug: melphalan;   Biological: aldesleukin;   Biological: sargramostim;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
39 Active, not recruiting Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, And Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Drug: carboplatin;   Drug: paclitaxel;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Other: laboratory biomarker analysis
40 Recruiting Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Conditions: HER2-negative Breast Cancer;   Inflammatory Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Romidepsin;   Drug: Abraxane

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years